Rutgers Cancer Institute

Modeling Therapy Sequence for Advanced Cancer: A Microsimulation Approach Leveraging Electronic Health Record Data

Purpose: Many patients with advanced cancers undergo multiple lines of treatment. Optimal therapy sequence (ie, what therapies are given and in what order) is often unknown. We developed methods for estimating quality-adjusted outcomes and cost-effectiveness of therapy sequences,...

Real‐world outcomes of nivolumab‐ AVD and brentuximab vedotin‐ AVD in paediatric and adult advanced‐stage Hodgkin lymphoma

Summary Brentuximab vedotin (BV)‐doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)‐AVD have transformed the frontline treatment of advanced‐stage Hodgkin lymphoma (HL), yet real‐world comparative data remain limited. In this multicentre retrospective study across 1...

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer

ROS1-targeted therapies have improved outcomes in ROS1-positive non-small cell lung cancer (NSCLC), but acquired resistance, CNS progression, and off-target toxicities remain important limitations. Zidesamtinib (Jideytro ® , NVL-520) is a next-generation, brain-penetrant, tropomy...